PRT-811 by Prelude Therapeutics for CNS Lymphoma: Likelihood of Approval
PRT-811 is under clinical development by Prelude Therapeutics and currently in Phase I for CNS Lymphoma. According to GlobalData, Phase I drugs for CNS Lymphoma does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the PRT-811 LoA Report. Buy the report here.GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.PRT-811 overviewPRT-811 is under development for treatment of advanced solid tumors including CNS lymphoma, high grade glioma, glioblastoma multiforme, uveal melanoma and myelofibrosis. It is administered through oral route. The drug candidate acts by targeting the protein arginine N methyltransferase 5 (PRMT5).Prelude Therapeutics overviewPrelude Therapeutics (Prelude) is a clinical-stage precision oncology company developing innovative drug candidates targeting critical cancer cell pathways. The company product pipeline includes PRT1419, a potent, selective inhibitor of MCL1, PRT2527, a potent and highly selective CDK9 inhibitor and PRT3645, a next-generation CDK4/6 inhibitor. Prelude others pipeline includes PRT3789 a first-in-class SMARCA2/BRM protein degraded. It also carries out clinical trials. The company serves throughout the US . Prelude is headquartered in Wilmington, Delaware, the United States. For a complete picture of PRT-811's drug-specific PTSR and LoA scores, buy the report here.
PRT-811is under clinical development by Prelude Therapeutics and currently in Phase I for CNS Lymphoma.
What's Your Reaction?
